Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Taltz for Adult Psoriatic Arthritis

FirstWord Pharma news release; 2017 Dec 1

Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA). Taltz was first approved by the FDA in March 2016 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Indications: Taltz is a humanized interleukin-17A antagonist indicated for the treatment of adults with active PsA.

Dosage/administration: For PsA, the recommended dose is 160 mg by subcutaneous injection (2 80 mg injections) at week 0, followed by 80 mg every 4 weeks. For PsA patients with coexistent moderate-to-severe plaque psoriasis, refer to the dosing regimen for plaque psoriasis. Taltz may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (DMARD).

Adverse reactions: Most common (≥1%) adverse reactions associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.


Lilly’s Taltz (ixekizumab) receives US FDA approval for the treatment of active psoriatic arthritis. [news release]. Indianapolis, IN: Eli Lilly and Company. December 2, 2017. Accessed December 4, 2017.

This Week's Must Reads

Hyperlipidemia Screening Poor in Persons with RA, Rheumatology (Oxford); ePub 2018 Jun 27; Schmidt, et al

Patient Confusion About Global Assessment for RA, Arthritis Care Res; ePub 2018 Jun 28; Hirsh, et al

Shared Decision-Making in RA at Point-of-Care, Arthritis Care Res; ePub 2018 Jun 28; Hsiao, et al

Examining Adiponectin Role in Rheumatoid Arthritis, PLoS One; ePub 2018 Jun 25; Hughes-Austin, et al

Online Resources for Disease Self-Management in RA, Clin Rheumatol; 2018 Jul; des Bordes, Gonzalez, et al

Must Reads in FDA Actions

FDA Approves Olumiant for Rheumatoid Arthritis, Eli Lilly, Incyte news release; 2018 Jun 1

FDA Approves Consensi for Osteoarthritis Pain, FirstWord Pharma news release; 2018 May 31

FDA Approves Prolia for GIOP in Men and Women, FirstWord Pharma news release; 2018 May 21

FDA Approves Xeljanz/Xeljanz XR for Adult PsA, Pfizer news release; 2017 Dec 14

FDA Approves New Pfizer Biosimilar Ixifi, Pfizer news release; 2017 Dec 13